Last month, some of the world’s leading neurologists, researchers, and scientists working in multiple sclerosis and related neurological diseases like neuromyelitis optica spectrum disorder (NMOSD) arrived in Toronto, Canada, for the 10th Joint ACTRIMS-ECTRIMS Meeting. ECTRIMS, the European Committee for Treatment and Research in Multiple Sclerosis, is…
Ultomiris (ravulizumab)
A global clinical trial testing Ultomiris (ravulizumab-cwvz) in adults with neuromyelitis optica spectrum disorder (NMOSD) found that the treatment kept patients free of relapses for more than 4.5 years. When compared with data from an external group of NMOSD patients given a placebo in a previous trial, the…
Ultomiris (ravulizumab-cwvz) was associated with sustained disease control in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether they had been previously treated off-label with rituximab. That’s according to a new analysis of data from the Phase 3 CHAMPION-NMOSD clinical trial (NCT04201262), whose results supported…
Note: This column describes the author’s own experiences with Ultomiris (ravulizumab-cwvz). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. When Alexion Pharmaceuticals first approached me about being featured for Rare Disease Day on Feb. 28, I initially declined the offer.
The first time I sat in the infusion chair to receive Ultomiris (ravulizumab-cwvz), I felt something I hadn’t experienced for a long time after being diagnosed with neuromyelitis optica spectrum disorder (NMOSD): hope. I needed this therapy to bring stability back to my life, to spend less time in…
Ultomiris (ravulizumab), an approved infusion therapy for adults with neuromyelitis optica spectrum disorder (NMOSD), is closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Alexion, AstraZeneca Rare Disease. The company signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA).
The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…
Note: This column describes the author’s early experiences with Ultomiris (ravulizumab-cwvz) and refers to past therapies she’s tried. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. I find myself whispering silent prayers throughout the day, pleading for my neuromyelitis…
None of the neuromyelitis optica spectrum disorder (NMOSD) patients in the Phase 3 CHAMPION-NMOSD clinical trial have had a disease relapse while on Ultomiris (ravulizumab-cwvz) treatment for a median of more than 2.5 years. These findings were shared by Sean Pittock, MD, the trial’s principal investigator, at the…
The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 (AQP4) protein. About 75% of people with NMOSD produce antibodies that bind to AQP4, according to the therapy’s developer, Alexion…
Recent Posts
- Early trial of experimental CAR T-cell therapy seeks people with NMOSD
- Because patients are the reason for the research, we deserve a seat at the table
- Disability in NMOSD patients may worsen even without relapses
- Aging with NMOSD: How I’m facing the future with hope
- Smoking hinders NMOSD relapse recovery, review study shows